https://orcid.org/0000-0003-1223-5694
References
- ISAPS international survey on aesthetic/cosmetic procedures performed in 2017. 2018 Available from: https://www.isaps.org/wp-content/uploads/2018/10/ISAPS_2017_International_Study_Cosmetic_Procedures.pdf Accessed 122, 2019.
- Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840–849. doi:10.1067/mjd.2002.12135612063480
- Moers-Carpi M, Carruthers J, Fagien S, et al. Efficacy and safety of onabotulinumtoxinA for treating crow’s feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatol Surg. 2015;41(1):102–112. doi:10.1097/DSS.000000000000022025485803
- Carruthers J, Rivkin A, Donofrio L, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow’s feet lines and glabellar lines. Dermatol Surg. 2015;41(6):702–711. doi:10.1097/DSS.000000000000035725993609
- Baumann L, Dayan S, Connolly S, et al. Duration of clinical efficacy of onabotulinumtoxinA in crow’s feet lines: results from two multicenter, randomized, controlled trials. Dermatol Surg. 2016;42(5):598–607. doi:10.1097/DSS.000000000000075727110893
- Harii K, Kawashima M, Furuyama N, Lei X, Hopfinger R, Lee E. OnabotulinumtoxinA (Botox) in the treatment of crow’s feet lines in Japanese subjects. Aesthetic Plast Surg. 2017;41(5):1189–1197. doi:10.1007/s00266-017-0844-9
- Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg. 2008;32(5):724–730. doi:10.1007/s00266-008-9199-618663516
- Wu Y, Zhao G, Li H, et al. Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2010;36(1):102–108. doi:10.1111/j.1524-4725.2009.01390.x20002637
- Won CH, Kim HK, Kim BJ, et al. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. Int J Dermatol. 2015;54(2):227–234. doi:10.1111/ijd.2015.54.issue-225311357
- Botox Cosmetic [package insert]. Dublin, Ireland: Allergan plc; 2017.
- Post-marketing safety management of drugs etc—guideline on re-evaluation tasks of new drugs etc [Handbook-0019-03]. 2018 Available from: https://www.mfds.go.kr/eng/index.do Accessed 72, 2019.
- Haque A, Daniel S, Maxwell T, Boerstoel M. Postmarketing surveillance studies-an industry perspective on changing global requirements and implications. Clin Ther. 2017;39(4):675–685. doi:10.1016/j.clinthera.2017.03.01128392076
- Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407–415. doi:10.1016/j.jaad.2005.06.01116112345
- Brin MF, Boodhoo TI, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009;61(6):961–970. doi:10.1016/j.jaad.2009.06.04019744746
- Beer KR, Boyd C, Patel RK, Bowen B, James SP, Brin MF. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol. 2011;10(1):39–44.21197522